Adrenergic beta-Antagonists / therapeutic use ; Calcium Channel Blockers / therapeutic use ; Cardiomyopathy, Hypertrophic* / drug therapy ; Humans
Keywords
Hypertrophic cardiomyopathy ; Myosin inhibitors ; Medical therapy
Abstract
The perception of HCM has shifted from a disease leading to sudden death to a condition requiring lifelong management. Given its relatively high prevalence and the need for ongoing treatment, the medication-based management of symptoms and comorbidities in these patients is crucial (Fig. 4). Research on the pathophysiology and genetic characteristics of HCM is ongoing, and new mechanism-based drugs are continually being developed. Therefore, an appropriate application of pharmacotherapy, considering the individual characteristics of each patient, is important. Additionally, patient education and lifestyle management should be integrated to achieve the sustained effectiveness of medical therapy. Ongoing drug development underscores the importance of health care providers staying regularly informed about emerging therapies.